Carbamazepine EP Impurity D

An insight into the role of additives in controlling polymorphic outcome: a CO2-antisolvent crystallization process of carbamazepine
Luis Padrela, Jacek Zeglinski, and Kevin M. Ryan
Cryst. Growth Des. 2017, 17, 9, 4544–4553
 
Nanographitic impurities are responsible for electrocatalytic activity of carbon nanotubes towards oxidation of carbamazepine
Elaine Lay Khim Chng, Martin Pumera
Electrochemistry Communications Volume 13, Issue 8, August 2011, Pages 781-784
 
Liquid Chromatographic Methods for Assay of Carbamazepine, 10,11-Dihydrocarbamazepine, and Related Compounds in Carbamazepine Drug Substance and Tablets
Terry D Cyr, Fumiko Matsui, Roger W Sears, Norman M Curran, Edward G Lovering
Journal of Association of Official Analytical Chemists, Volume 70, Issue 5, 1 September 1987, Pages 836–840
 
Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography–tandem mass spectrometry and semi-preparative chromatographic isolation
Saji Thomas a,∗, Chandra S. Mathela b, Ashutosh Agarwal a, Saroj Kumar Paul
Journal of Pharmaceutical and Biomedical Analysis Volume 56, Issue 2, 10 September 2011, Pages 423-428

Carbamazepine EP Impurity D is chemically 5H-Dibenzo[b,f]azepine (as per EP) ; 5H-Dibenz[b,f]azepine (as per USP). It is also known as Carbamazepine USP Related Compound B ; Iminostilbene (EP). Carbamazepine EP Impurity D is supplied with detailed characterization data compliant with regulatory guideline. Carbamazepine EP Impurity D can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Carbamazepine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.